The overall purpose of the Animal Models Core (Core D) is to facilitate the accomplishment of the translational research goals and objectives of the SPORE by providing investigators with assistance in the design and generation of transgenic and knockout/knockin mouse strains, a centralized repository for these mouse strains, and material of common interest, such as dissected tissues, DNA, RNA, or protein extracts from these mouse strains.
The specific aims of the Animal Models Core are to: 1. Generate and provide genetically engineered mouse models and patient-derived xenograft models as needed by SPORE investigators. 2. Provide small animal imaging, histopathologic analyses of tumor specimens, design and conduct preclinical trials, and serve as a repository and breeding service of mouse strains as requested by SPORE investigators. 3. Provide SPORE laboratories with dissected tissue specimens, DNA, RNA, and proteins from the various mouse models utilized by our investigators.

Public Health Relevance

The Animal Models Core is an essential component of our SPORE in Prostate Cancer because it facilitates the timely conduct of research by centralizing services designed to prioritize the needs of our SPORE investigators: maintaining colonies of mice ready for use in preclinical studies and procuring and banking tissue from these mice for characterization of molecular markers and for RNA, DNA, and protein studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-20
Application #
9998853
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-14
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
20
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Scher, Howard I; Graf, Ryon P; Schreiber, Nicole A et al. (2018) Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol 4:1179-1186
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Roobol, Monique J; Carlsson, Sigrid V (2018) The ERSPC Study: Quality Takes Time and Perseverance. Clin Chem :
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467
Van Calster, Ben; Wynants, Laure; Verbeek, Jan F M et al. (2018) Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol 74:796-804
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386

Showing the most recent 10 out of 505 publications